Citius Pharmaceuticals’ latest quarterly disclosure for Q2 fiscal 2026 underscores a revenue plateau despite launching LYMPHIR™ in early 2025. The company continues to grapple with net losses and a strained liquidity position as it activates distribution agreements with major healthcare distributors such as McKesson and Cardinal Health. Its business model hinges on proprietary pharmaceutical products and strong distribution partnerships, but near-term growth remains contingent on improved market adoption and capital access. With no material change in risk factors, financial sustainability and execution efficiency are key watchpoints going forward.